Deals
BioBlast Pharma Raises $7M at 24% Discount via Roth Capital Partners
|
BioBlast Pharma Limited (NASDAQ GM:ORPN) announced that it has raised $6,696,000 in a Registered Direct transaction.
Growth Capitalist (https://growthcapitalist.com/category/premium-articles/page/52/)
Growth capital news and research from Growth Capital Investor, the journal of emerging growth company finance. Subscription required.
BioBlast Pharma Limited (NASDAQ GM:ORPN) announced that it has raised $6,696,000 in a Registered Direct transaction.
Investors led by Baupost Group are buying $165 million in convertible secured notes from Orexigen Therapeutics (OREX) to help fund the commercialization of Contrave as Orexigen buys the U.S. rights to the anti-obesity drug.
International Stem Cell Corporation (OTC:ISCO) announced that it has raised $6,310,000 in a Convertible Preferred Stock transaction.
Condor Hospitality Trust (NASDAQ GM:CDOR) announced that it has raised $30,000,000 in a Convertible Preferred Stock transaction.